Previous 10 | Next 10 |
home / stock / anvs / anvs articles
Merck (NYSE: MRK) announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP...
Novo Nordisk (NYSE: NVO) lost 2.2% on Jun 26 after the company announced the failure of a late-stage study evaluating ocedurenone to trea...
MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical dru...
Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...
Intellia Therapeutics' (NASDAQ: NTLA) shares gained 10% on Jun 3 after the company reported encouraging long-term data from the phase I portion...
AbbVie (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has a...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 0.1% on Monday. The Dow traded up 0.19% to 38,313.56 ...
Annovis Bio Inc (NASDAQ:ANVS) shares plunged after the company released data from its Phase 2/3 Alzheimer study of buntanetap in mil...
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily ...
News, Short Squeeze, Breakout and More Instantly...
The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients Following the announcement of these positive results, the company’s stock price surged by 76% The data revealed that while 12%...
Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company’s research focuses on inhibiting the production of ...
Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food an...